The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

Inclusion Criteria: PART 1: 1. Healthy males , aged 18-65; 2. BMI 18 \~ 30 kg/m2; 3. Subjects in general good health. No clinically significant findings in Physical examination and auxiliary examination. PART 2: 1. premenopausal females, aged 18-45; 2. BMI 18 \~ 30 kg/m2; 3. Subjects in general good health. No clinically significant findings in Physical examination and auxiliary examination. Exclusion Criteria: PART 1 1. Testosterone (T) \< 12 nmol/L; 2. ALT or AST or total bilirubin exceeds the upper limit of normal; 3. Those with positive nicotine test and alcohol breath test before administration, and those with positive drug screening before administration; 4. Use of any medication within 1 month before administration; or use of medication that does not exceed 5 half-lives, whichever is longer; 5. Subjects with chronic diseases or serious diseases that affect drug absorption, distribution, metabolism and excretion; 6. Blood donation or donation of blood components within 1 month before screening, or loss of blood equivalent to at least 200 mL, or transfusion within 2 months; 7. Use of GnRH agonists and GnRH antagonists within 6 months before screening and use of any androgens and antiandrogens within 5 half-lives before screening; 8. Subjects with severe infection, severe trauma or major surgery within 6 months before screening; 9. Positive results of infectious disease screening . 10. Allergic constitution or allergy to two or more kinds of food and drugs, including known history of allergy to the study drug or any component of the study drug. PART 2: 1. Pregnant or breast feeding; 2. FSH≥25U/L; 3. Positive serum pregnancy test (serum β-HCG test) result; 4. Abnormal uterine bleeding within 3 months prior to screening 5. ALT or AST or total bilirubin exceeds the upper limit of normal; 6. Those with positive nicotine test and alcohol breath test before administration, and those with positive drug screening before administration; 7. Use of any medication within 1 month before administration; or use of medication that does not exceed 5 half-lives, whichever is longer; 8. Subjects with chronic diseases or serious diseases that affect drug absorption, distribution, metabolism and excretion; 9. Blood donation or donation of blood components within 1 month before screening, or loss of blood equivalent to at least 200 mL, or transfusion within 2 months; 10. GnRH agonist use 6 months prior to Screening and GnRH antagonist or any sex hormone use 2 months prior to Screening. 11. Subjects with severe infection, severe trauma or major surgery within 6 months before screening 12. Positive results of infectious disease screening . 13. Allergic constitution or allergy to two or more kinds of food and drugs, including known history of allergy to the study drug or any component of the study drug.